Literature DB >> 21916599

Genomic instability in cultured stem cells: associated risks and underlying mechanisms.

Andrew L Ross1, Daniel E Leder, Jonathan Weiss, Jan Izakovic, James M Grichnik.   

Abstract

Embryonic stem cells, mesenchymal stem cells and induced pluripotent stem cells expanded in vitro exhibit genomic instability. Commonly reported abnormalities include aneuploidy, deletions and duplications (including regions also amplified in cancer). Genomic instability confers an increased risk of malignant transformation that may impact the safety of cultured stem cell transplantation. Possible mechanisms responsible for this genomic instability include DNA repair mechanism abnormalities, telomere crisis, mitotic spindle abnormalities and inappropriate induction of meiotic pathways. Prior to widespread use of these cells in regenerative medicine, it will be critical to gain an understanding of the mechanisms responsible for genomic instability to develop strategies to prevent the accrual of chromosomal defects during expansion in vitro.

Entities:  

Mesh:

Year:  2011        PMID: 21916599     DOI: 10.2217/rme.11.44

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  10 in total

Review 1.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

Review 2.  Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells.

Authors:  Paul S Knoepfler
Journal:  Regen Med       Date:  2012-07-26       Impact factor: 3.806

3.  Implications of aneuploidy for stem cell biology and brain therapeutics.

Authors:  Sylvie Devalle; Rafaela C Sartore; Bruna S Paulsen; Helena L Borges; Rodrigo A P Martins; Stevens K Rehen
Journal:  Front Cell Neurosci       Date:  2012-09-05       Impact factor: 5.505

4.  Diagnostic role of chromosomal instability in melanoma.

Authors:  Nitika Dabas; Diana M Byrnes; Ashley M Rosa; Mark S Eller; James M Grichnik
Journal:  J Skin Cancer       Date:  2012-10-18

5.  Mesenchymal stromal cells of osteosarcoma patients do not show evidence of neoplastic changes during long-term culture.

Authors:  Anne-Marie Cleton-Jansen; Arjan C Lankester; Emilie P Buddingh; S Eriaty N Ruslan; Christianne M A Reijnders; Karoly Szuhai; Marieke L Kuijjer; Helene Roelofs; Pancras C W Hogendoorn; R Maarten Egeler
Journal:  Clin Sarcoma Res       Date:  2015-06-23

6.  Cell Expansion-Dependent Inflammatory and Metabolic Profile of Human Bone Marrow Mesenchymal Stem Cells.

Authors:  Patricia Prieto; María Fernández-Velasco; María E Fernández-Santos; Pedro L Sánchez; Verónica Terrón; Paloma Martín-Sanz; Francisco Fernández-Avilés; Lisardo Boscá
Journal:  Front Physiol       Date:  2016-11-16       Impact factor: 4.566

Review 7.  Enriched Environment and Exercise Enhance Stem Cell Therapy for Stroke, Parkinson's Disease, and Huntington's Disease.

Authors:  Reed Berlet; Dorothy Anne Galang Cabantan; Daniel Gonzales-Portillo; Cesar V Borlongan
Journal:  Front Cell Dev Biol       Date:  2022-03-03

8.  Large scale expansion of human umbilical cord cells in a rotating bed system bioreactor for cardiovascular tissue engineering applications.

Authors:  Anne Reichardt; Bianca Polchow; Mehdi Shakibaei; Wolfgang Henrich; Roland Hetzer; Cora Lueders
Journal:  Open Biomed Eng J       Date:  2013-06-14

9.  Increased insulin-like growth factor 1 production by polyploid adipose stem cells promotes growth of breast cancer cells.

Authors:  Roberta Fajka-Boja; Annamária Marton; Anna Tóth; Péter Blazsó; Vilmos Tubak; Balázs Bálint; István Nagy; Zoltán Hegedűs; Csaba Vizler; Robert L Katona
Journal:  BMC Cancer       Date:  2018-09-05       Impact factor: 4.430

Review 10.  Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges.

Authors:  Juan Antonio Guadix; Javier López-Beas; Beatriz Clares; José Luis Soriano-Ruiz; José Luis Zugaza; Patricia Gálvez-Martín
Journal:  Pharmaceutics       Date:  2019-10-24       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.